The Affordable Prescriptions for Patients Act aims to make it easier for companies to sell cheaper versions of biologic drugs, known as biosimilars. The bill limits the number of patents that the original drug manufacturer can use to block these biosimilar products in court, particularly for patents filed after the drug has been approved for four years. However, this limit does not apply to certain patents related to how the drug is used. Courts can allow more patents to be used if there is a good reason to do so.
The bill has been praised for its potential to lower drug costs for patients by facilitating the entry of more affordable biosimilar drugs into the market. Supporters argue that it encourages competition and innovation in the pharmaceutical industry, ultimately benefiting consumers who struggle with high medication prices.
Critics of the Affordable Prescriptions for Patients Act express concerns that limiting patent assertions could undermine the incentive for pharmaceutical companies to invest in new drug development. They argue that it may lead to a reduction in the quality of biologic drugs and could create legal uncertainties that might discourage innovation in the biotech sector.
All donations are from individuals employed by Applied Materials, Inc. There is no direct connection between the company and the pharmaceutical industry, which reduces the conflict-of-interest risk for the Affordable Prescriptions for Patients Act.
